By Chris Hutching
Friday 17th September 2004 |
Text too small? |
The health board contracts account for 25-30% of the company's pre-tax revenue but there were concerns after the tender dragged on for several months.
The tender is in two parts, one of which is yet to be resolved.
The board confirmed the pharmaceuticals tender, which accounts for almost 60% of the combined value of the two tenders (Ebos' subsidiary, Health Support, is the incumbent provider). A second tender for medical consumables is still being worked through, with a decision expected before Christmas.
The sale of shares by Rangatira apparently took Ebos directors by surprise, coming on the same day (last Friday) that Ebos confirmed the pharmaceuticals contract.
About one million shares were sold at $3.80 a share on the same day and another 1.7 million shares were sold via institutions and brokers at an average $3.87 a share.
But the on-market retail price hit a record $4.10 (sell) before settling back at $4.03.
No comments yet
PaySauce Quarterly Market Update - June 2024
Manawa Energy - Annual Meeting and Director Nominations
SKO - Annual Shareholders Meeting Materials
VGL - 2024 Half Year Results Announcement Date
TruScreen Group Limited ("TRU") - Late Annual Report
ARB - Sale of In Vitro Business
NZK - Change of External Auditor
SCT - Scott lands major contracts for MHL in Europe
July 2nd Morning Report
PFI - Details of FP24 Results Webcast